Novo Nordisk's two UBT251 drug interaction studies continue recruiting participants
Both Phase 1 trials testing UBT251 alongside common medications, including a contraceptive and a CYP enzyme cocktail, remain open for enrollment.
Novo Nordisk continues recruiting for two Phase 1 studies examining how UBT251 interacts with other drugs in people with overweight or obesity.
- The trial "An Open-label, Single-sequence, Crossover Study Investigating the Influence of UBT251 on Pharmacokinetics of Index Substrates for Cytochrome P450 Enzymes in Participants With Overweight or Obesity" (NCT07710768) is recruiting. A cocktail containing warfarin, caffeine, and midazolam will be administered at predefined study visits to evaluate the effect of UBT251 on the pharmacokinetics of CYP enzyme substrates.1 The study has an estimated enrollment of 44 participants1 at Altasciences Clinical LA, Inc., Cypress, California, United States (recruiting)1.
- A second trial, "A Single-Centre, Open-Label Study of the Effect of UBT251 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) and Gastric Emptying in Women of Non-Childbearing Potential With Overweight or Obesity" (NCT07710729), is also recruiting. An oral contraceptive will be administered during baseline and treatment assessment periods to evaluate the effect of UBT251 on oral contraceptive pharmacokinetics.2 The study has an estimated enrollment of 40 participants2 at Altasciences Clinical Company, Inc, Montreal, Quebec, Canada (recruiting)2.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.